CRBP
Corbus Pharmaceuticals Holdings, Inc.
Next earnings Aug 3, 2026 · consensus $-1.28 EPS
Last earnings +3.5% on 2026-05-12
$8.74
▲ +5.94%$8.74▲ +10.77%
over 1Y
L $6.90EODHDH $19.36
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.9%
1W+5.2%
1M+11.8%
3M+0.3%
YTD+11.1%
1Y+10.8%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 16 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.14x); but revenue fell -100.0% YoY.
Revenue (FY2022) $0.00 · FY2022
Corbus Pharmaceuticals Holdings, Inc. shows $0.00 in FY2022 revenue (-100.0% YoY), and -53.2% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $882K | $0.00 | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$56.0M | -$39.8M | -$45.1M | -$48.7M | -$85.3M |
| Net income | -$45.6M | -$42.3M | -$44.6M | -$40.2M | -$78.5M |
| Diluted EPS | -$11.15 | -$10.15 | -$10.31 | -$3.68 | -$5.90 |
| Net margin | -5176.4% | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$142M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-50.7%
FCF yield-41.6%
Quality & risk
ROIC (est.)-41.2%
Free cash flow-$64.5M
Total debt$15.9M
Net cash$12.6M
Altman Z-Score-0.76 distress
Piotroski F-Score2/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+45.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Reg FD disclosure2026-05-26
- 8-K Officer / director change2026-05-21
- 8-K Officer / director change2026-05-14
- 8-K Earnings results2026-05-12
- 10-Q Quarterly report2026-05-12
- 8-K Officer / director change2026-04-16
- 8-K Reg FD disclosure2026-04-14
- DEF 14A Proxy statement2026-04-02
- S-3 Shelf registration (potential raise)2026-03-11
Recent filings
all on EDGAR ↗S-8Filing2026-06-17open ↗4Period ending 2026-06-102026-06-11open ↗4Period ending 2026-06-102026-06-11open ↗4Period ending 2026-06-102026-06-11open ↗4Period ending 2026-06-022026-06-03open ↗S-8Filing2026-05-29open ↗8-KPeriod ending 2026-05-262026-05-26open ↗4Period ending 2026-05-212026-05-22open ↗3Period ending 2026-05-212026-05-22open ↗4Period ending 2026-05-192026-05-21open ↗4Period ending 2026-05-192026-05-21open ↗4Period ending 2026-05-192026-05-21open ↗
Frequently asked
- Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) a buy?
- CRBP currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.14x); but revenue fell -100.0% YoY.
- What is Corbus Pharmaceuticals Holdings, Inc.'s quality score?
- CRBP scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001595097, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 7:02:43 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.